Tilray Brands (NASDAQ:TLRY – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Insider & Institutional Ownership
9.3% of Tilray Brands shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Tilray Brands and Gyre Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tilray Brands | 1 | 3 | 2 | 1 | 2.43 |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
Risk and Volatility
Tilray Brands has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.
Valuation & Earnings
This table compares Tilray Brands and Gyre Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tilray Brands | $915.45 million | 0.61 | -$121.40 million | ($1.08) | -3.77 |
| Gyre Therapeutics | $116.59 million | 7.01 | $5.03 million | ($0.21) | -34.90 |
Gyre Therapeutics has lower revenue, but higher earnings than Tilray Brands. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Tilray Brands and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tilray Brands | -13.11% | -7.76% | -5.59% |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
Summary
Gyre Therapeutics beats Tilray Brands on 8 of the 14 factors compared between the two stocks.
About Tilray Brands
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
